Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHT105 in Relapsed/Refractory Immune Thrombocytopenia
NCT07811622Not yet recruiting
- Sponsor
- Nanjing Miracle Biotechnology
- Start
- Sep 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Open-label, single-arm trial of CHT105 in immune thrombocytopenia (ITP), sponsored by Nanjing Miracle Biotechnology. Primary endpoints: Adverse Events at 52 weeks and Complete response rate and partial response rate at 24 weeks. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
CHT105
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT07811622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07811622.